vTv Therapeutics

vTv Therapeutics is a biopharmaceutical company with a strong focus on addressing unmet medical needs through innovative therapeutic discoveries. Since its establishment in 1998, the company has prioritized the development of small molecule clinical and pre-clinical drug candidates targeting a wide spectrum of diseases, including central nervous system disorders, metabolic disorders, inflammation, and cancer.

Key to vTv Therapeutics' success is its commitment to leveraging proprietary technology, fostering strategic collaborations, and nurturing a talented scientific team, which has culminated in the establishment of a fully integrated pharmaceutical entity.

The company's lead candidate, azeliragon, specifically designed for Alzheimer's disease treatment, has shown promising results in Phase 2 clinical trials, prompting the FDA to grant it Fast Track Designation and special agreement on its Phase 3 protocol through a Special Protocol Assessment. The Phase 3 study for patients with mild Alzheimer's disease commenced in April 2015, aiming to establish the candidate's disease-modifying potential.

Furthermore, vTv Therapeutics is making significant strides in the clinical development of TTP399, a novel liver-selective Glucokinase Activator for type 2 diabetes treatment. In a Phase 2a study, TTP399 effectively normalized patients' HbA1c levels without causing hypoglycemia after just six weeks of treatment. Currently, a six-month Phase 2 study is ongoing.

The company's most recent investment of $51.00M in Post-IPO Equity at 28 February 2024 was led by T1D Fund and Samsara BioCapital, signaling growing confidence and support from prominent investors in vTv Therapeutics' breakthroughs in therapeutics.